Introduction
============

Glioma is the most common type of intracranial primary malignant tumor, which is associated with a poor median survival time of \<15 months ([@b1-ijmm-41-03-1339]). Existing therapies include surgical removal, chemotherapy and radiotherapy; however, they are often unsuccessful ([@b1-ijmm-41-03-1339]--[@b3-ijmm-41-03-1339]). The difficulties in curing glioma are due to uncontrollable proliferation and infiltrative growth ([@b1-ijmm-41-03-1339]), which are considered to be largely attributed to aberrant signaling ([@b4-ijmm-41-03-1339]).

Mitogen-activated protein kinase (MAPK) cascades have been widely studied and are reported to be markedly altered in glial tumors ([@b4-ijmm-41-03-1339],[@b5-ijmm-41-03-1339]). Extracellular signal-regulated kinase 1/2 (ERK1/2) is a crucial member of the MAPK family, which contains a conserved and dual-specificity motif (T-E-Y) that can be phosphorylated on threonine (Thr)^202^ and tyrosine (Tyr)^204^ residues. ERK1/2 is involved in the regulation of cell cycle progression, proliferation, differentiation, senescence and apoptosis ([@b6-ijmm-41-03-1339]). In human glioma tissues, the expression levels of phosphorylated (p)-ERK1/2 are significantly increased compared with in normal brain tissues, and expression is correlated with glioma grade ([@b7-ijmm-41-03-1339],[@b8-ijmm-41-03-1339]), thus suggesting that aberrant upregulation or activation of ERK1/2 may lead to malignant progression of glioma. However, pharmacological inhibitors of ERK1/2 are cytostatic at best, and only in a subset of patients ([@b4-ijmm-41-03-1339]), thus indicating that other unidentified factors or compensatory signals may affect the survival and growth of tumor cells.

Nitric oxide (NO) is a short-lived free radical, which serves critical roles in the regulation of cardiovascular, immune and central nervous systems ([@b9-ijmm-41-03-1339]). S-nitrosylation refers to the covalent addition of a NO group to a cysteine (Cys) thiol, and is considered one of the important ways through which NO functions ([@b10-ijmm-41-03-1339]). Protein S-nitrosylation can alter spatial structure of proteins, and increase or decrease protein activity and stability and subsequent signal transduction and cellular processes ([@b11-ijmm-41-03-1339]). Feng *et al* reported that ERK1 harbors six Cys residues and that Cys^183^ is the key site for ERK1 nitrosylation ([@b12-ijmm-41-03-1339]). The present study aimed to investigate the association between ERK1/2 nitrosylation and ERK1/2 phosphorylation, and the effects of ERK1 S-nitrosylation at Cys^183^ on glioma cell survival.

The results of the present study demonstrated that treatment with the NO donors sodium nitroprusside (SNP) or S-nitrosoglutathione (GSNO) induced an increase in ERK1/2 S-nitrosylation, and a reduction in ERK1/2 phosphorylation, which were accompanied by growth inhibition of U251 glioma cells. Mutational analysis \[Cys^183^ to alanine (Ala)^183^\] uncovered that S-nitrosylation of ERK1 attenuated ERK1/2 phosphorylation, inhibited cell survival and promoted apoptosis. In addition, the results detected an increase in phosphorylation of ERK1/2 and a decrease in ERK1/2 S-nitrosylation in human glioma tissues. These findings identified a novel mechanism of ERK1/2 underlying tumor cell development and apoptotic resistance in glioma.

Materials and methods
=====================

Reagents and antibodies
-----------------------

Methyl methylthiomethyl sulfoxide (MMTS), neocuproine, sodium ascorbate and GSNO were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). SNP was obtained from Beyotime Institute of Biotechnology (Haimen, China). PolyJet™ and Biotin-HPDP were purchased from Thermo fisher Scientific, Inc. (Waltham, MA, USA). Antibodies against Flag (F1084; 1:1,000; Sigma-Aldrich; Merck KGaA), ERK1/2 (ab17942; 1:1,000; Abcam, Cambridge, UK), p-ERK1/2 (sc-81492; 1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), and caspase-3 (GTX110543; 1:1,000; GeneTex, Inc., Irvine, CA, USA) were commercially available.

Cell culture
------------

The U251 glioma cell line was purchased from Shanghai Cell Bank, Type Culture Collection Committee, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in Dulbecco\'s modified Eagle\'s medium supplemented with 10% fetal bovine serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) in a cell incubator containing 5% CO~2~ under saturated humidity at 37°C. Cells were treated at 37°C with NO donors SNP (0--2 *µ*M) or GSNO (0--500 *µ*M) for 36 h or with SNP (2 *µ*M) or GSNO (500 *µ*M) for different time (0--36 or 48 h) prior to further analysis.

Cell viability detection
------------------------

Cell viability was measured using Cell Counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Kumamoto, Japan). A single cell suspension (5×10^3^/ml, 100 *µ*l) was seeded into a 96-well plate. Subsequently, 10 *µ*l CCK-8 reagent was added to each well and the plates were incubated for 2 h at 37°C. Finally, the absorbance was measured at 450 nm using a scanning microplate reader. Cell viability at individual time-points was normalized to the untreated group.

Flow cytometric apoptotic assay
-------------------------------

Cells were harvested and washed twice with ice-cold PBS, after which they were resuspended in 1X binding buffer \[0.01 M HEPES/NaOH (pH 7.4), 0.14 M NaCl, 2.5 mM CaCl~2~\] at a concentration of 10^6^ cells/ml. Subsequently, 100 *µ*l solution was transferred to a 5 ml cell culture tube and was treated with fluorescein isothiocyanate-conjugated Annexin V apoptosis detection kit I (BD Biosciences, Franklin Lakes, NJ, USA) according to the manufacturer\'s protocol. The cells were analyzed using flow cytometry (DiVa 8.0.1; BD Biosciences) and a total of 10,000 cells/sample were analyzed to determine the percentage of apoptotic cells.

Western blot analysis
---------------------

Total protein was extracted from the cells or tissues, as described previously ([@b13-ijmm-41-03-1339]). Protein concentrations were determined by a BCA protein assay kit (Beyotime Institute of Biotechnology) according to the manufacturer\'s instructions. Equal amounts of protein (30 *µ*g) were mixed with SDS sample buffer, separated by 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes (EMD Millipore, Billerica, MA, USA). The membranes were then incubated with 3% bovine serum albumin (Sigma-Aldrich; Merck KGaA) in PBS at room temperature for 2 h, and were treated with primary antibodies overnight at 4°C. β-actin (sc-47778; 1:1,000; Santa Cruz Biotechnology, Inc.) was used as a protein-loading control. The next day, membranes were incubated with horseradish peroxidase-conjugated goat anti-rabbit (31460)/mouse (31430) immunoglobulin G (1:4,000; Invitrogen; Thermo fisher Scientific, Inc.) at room temperature for 2 h and were then detected using a standard chemiluminescence detection system (Pierce; Thermo fisher Scientific, Inc.). Band densities were analyzed using ImageJ software (Image J 1.43u; National Institute of Health, Bethesda, MD, USA).

NO detection
------------

NO levels were determined by Griess assay using a commercial kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). Cell supernatants (100 *µ*l) were thoroughly mixed with reagent I (200 *µ*l). The supernatants were obtained simply by a 200 *µ*l pipette from the cell medium. Subsequently, reagent II (100 *µ*l) was added and mixed for 10 min at room temperature, followed by centrifugation at 1,700 × g for 15 min at room temperature. Finally, 160 *µ*l supernatants were mixed with 80 *µ*l chromogenic reagent for 15 min at room temperature. The optical density of the samples was measured using a spectrophotometer with absorbance set at 550 nm. Sodium nitrite was used as a standard.

Biotin switch assay
-------------------

Samples were lysed in non-denaturing lysis buffer (25 mM HEPES, 50 mM NaCl, 0.1 mM EDTA, 1% NP-40 and 1X protease inhibitor cocktail, pH 7.4). Protein concentration was determined using the bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). Protein lysates (2 mg) were diluted to a final volume of 1.8 ml using HEN buffer (100 mM HEPES, 1 mM EDTA and 0.1 mM neocuproine). Subsequently, 0.2 ml 25% SDS and 20 *µ*l 10% MMTS were added to block free thiols. After removing excess MMTS by acetone precipitation, the S-nitrosothiol (SNO) groups in the samples were reduced to thiols by 30 *µ*l sodium ascorbate (200 mM) and biotinylated by 30 *µ*l Biotin-HPDP (2.5 mg/ml). Finally, the biotinylated proteins were pulled down by streptavidin-agarose beads, and the beads were eluted by SDS loading buffer and subjected to western blot analysis.

Plasmids
--------

Full-length wild-type ERK1 (ERK1^WT^) cDNA clone was purchased from Sino Biological, Inc. (Beijing, China) and was subcloned into the 3xFlag vector. The primer sequences used for construction of Flag-ERK1^WT^ were as follows: Forward, 5′-CCGGAATTCATGGCGGCGGCGGCGGCTCA-3′ and reverse, 5′-CGCGGATCCGGGGGCCTCCAGCACTCCGG-3′. C183A mutant ERK1 (ERK1^C183A^) cDNA was obtained by polymerase chain reaction \[PCR; Tiangen Biotech (Beijing) Co., Ltd., Beijing, China\] with the Flag-ERK1^WT^ plasmid used as the template, and was then subcloned into the 3xFlag vector. The primer sequences used were as follows: forward, 5′-CCTTAAGATTGCTGATTTCGGCCTGGC-3′ and reverse, 5′-GCCGAAATCAGCAATCTTAAGGTCGCAG-3′. PCR thermocycling was performed as follows: 94°C for 3 min; followed by 35 cycles at 90°C for 30 sec, 60°C for 45 sec and 72°C for 90 sec; 72°C for 10 min; hold at 4°C. The authenticity of the plasmids was confirmed by DNA sequencing. Briefly, when U251 cells reached a confluency of 40--50%, the cell medium was replaced with 2 ml fresh DMEM medium at 30 min before transfection. Plasmid (1 *µ*g) and PolyJet™ reagent (3 *µ*l) were mixed in high glucose DMEM medium at room temperature. The mixture was evenly added into the medium and the cells were incubated at 37°C for 6--8 h before replacing the medium with 2 ml fresh medium. After 48 h, the cells were used for the experiments. Transient transfection was performed using PolyJet™ according to the manufacturer\'s protocol. Expression of proteins was verified by western blot analysis using ERK1/2 and Flag antibodies.

Glioma and noncancerous human brain tissue collection
-----------------------------------------------------

Human glioma specimens, collected during surgical resection, and noncancerous brain tissues, collected during internal decompression after cerebral trauma, were obtained from the Affiliated Hospital of Xuzhou Medical University (Xuzhou, China). The clinicopathological characteristics of all of the subjects are presented in [Table I](#tI-ijmm-41-03-1339){ref-type="table"}. Surgically removed tissues were sampled for histological diagnosis, and the remaining tissues were immediately frozen and stored in liquid nitrogen for further analysis. All glioma specimens had a confirmed pathological diagnosis and were classified according to World Health Organization criteria ([@b14-ijmm-41-03-1339]). Informed consent was obtained from all subjects, or legal guardians, and the present study was approved by the Medical Ethical Committee of Xuzhou Medical University.

Statistical analysis
--------------------

All quantitative data were obtained from at least three independent experiments and are presented as the means ± standard error of the mean \[SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA)\]. Data between two groups were assessed by Student\'s t-test, whereas one-way analysis of variance followed by Dunnett post hoc comparison was used to analyze data among three groups or more. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

NO donor treatment inhibits growth of glioma cells
--------------------------------------------------

According to the literature, treatment with the NO donor SNP for 30--40 h significantly inhibits the growth of human glioma cells ([@b15-ijmm-41-03-1339]); therefore, the present study conducted a CCK-8 assay to evaluate the concentration-dependent effects of SNP and GSNO on cell survival after 36 h in U251 cells. Cell viability was significantly reduced following treatment with 0.25 and 0.5 mM SNP or 100--200 *µ*M GSNO, and was reduced to a greater extent following treatment with 1 and 2 mM SNP or 250 and 500 *µ*M GSNO ([Fig. 1A and B](#f1-ijmm-41-03-1339){ref-type="fig"}). To determine the appropriate duration of high-dose SNP or GSNO treatment, U251 glioma cells were treated with 2 mM SNP or 500 *µ*M GSNO for 0, 6, 12, 24, 36 and 48 h. Significant inhibition of cell survival was observed when cells were exposed to 2 mM SNP for 36 h or 500 *µ*M GSNO for 36 and 48 h ([Fig. 1C and D](#f1-ijmm-41-03-1339){ref-type="fig"}). These results indicated that high doses of NO donors exert significant inhibitory effects on the growth of glioma cells.

NO donor treatment increases NO release into the cell supernatant
-----------------------------------------------------------------

To ascertain whether the NO donors SNP and GSNO could release NO, the Griess method was used to measure NO levels in the supernatant of cultured U251 cells. Significant increases in NO release were detected following treatment with 1 or 2 mM SNP ([Fig. 2A](#f2-ijmm-41-03-1339){ref-type="fig"}) and 250 or 500 *µ*M GSNO ([Fig. 2B](#f2-ijmm-41-03-1339){ref-type="fig"}). These data suggested that SNP and GSNO may breakdown to release NO into the culture supernatant of glioma cells.

NO donor treatment attenuates phosphorylation of ERK1/2 in glioma cells
-----------------------------------------------------------------------

The MAPK pathway has been reported to serve a critical role in cell survival ([@b6-ijmm-41-03-1339]), and increased phosphorylation of ERK1/2 has been detected in various grades of glioma ([@b7-ijmm-41-03-1339],[@b8-ijmm-41-03-1339]). The present study investigated the effects of NO donor treatment on the expression levels of p-ERK1/2 in glioma cells. Initially, a time-dependent assay was performed in U251 glioma cells. The expression levels of p-ERK1/2 were significantly reduced following treatment with 2 mM SNP or 500 *µ*M GSNO treatment for 24 and 36 h ([Fig. 3A and B](#f3-ijmm-41-03-1339){ref-type="fig"}). Subsequently, U251 cells were exposed to various concentrations of SNP or GSNO for 36 h. A concentration-dependent decrease in p-ERK1/2 expression was evident in response to SNP and GSNO treatment. Significant decreases in the expression levels of p-ERK1/2 were observed following treatment with 1 and 2 mM SNP ([Fig. 3C](#f3-ijmm-41-03-1339){ref-type="fig"}). Similarly, p-ERK1/2 expression was significantly reduced following 250 and 500 *µ*M GSNO treatment ([Fig. 3D](#f3-ijmm-41-03-1339){ref-type="fig"}). These data indicated that NO donor treatment, particularly in high concentrations, may attenuate the phosphorylation of ERK1/2 in glioma cells.

NO donor treatment promotes S-nitrosylation of ERK1/2 in glioma cells
---------------------------------------------------------------------

To determine whether ERK could be nitrosylated by NO, S-nitrosylation of ERK1/2 (SNO-ERK1/2) was analyzed by a biotin switch assay, followed by western blot analysis. Time- and dose-dependent increases in the levels of SNO-ERK1/2 were detected in response to GSNO treatment of U251 cells. The levels of ERK1/2-SNO were markedly increased at 24 and 36 h, and then returned to control levels at 48 h ([Fig. 4A](#f4-ijmm-41-03-1339){ref-type="fig"}). ERK1/2-SNO was initially detected following treatment with 250 *µ*M GSNO and was amplified with 500 *µ*M GSNO treatment ([Fig. 4B](#f4-ijmm-41-03-1339){ref-type="fig"}). These results suggested that ERK1/2 may be nitrosylated in a time- and dose-dependent manner.

S-nitrosylation of ERK1 is prevented by mutation at Cys^183^
------------------------------------------------------------

ERK1 has six Cys residues in its FASTA sequence ([Fig. 5A](#f5-ijmm-41-03-1339){ref-type="fig"}). A preliminary computational prediction indicated that Cys^183^ is the most probable site for nitrosylation, according to the previously reported nitrosylation motif (K/R/H/D/E+C+D/E) ([@b16-ijmm-41-03-1339]). Therefore, Cys^183^ was replaced with Ala, and the ERK1 mutant plasmid (ERK1^C183A^) was constructed. Transfection efficiency of ERK1^WT^ and ERK1^C183A^ was verified by western blot analysis using anti-Flag and anti-ERK1/2 antibodies ([Fig. 5B](#f5-ijmm-41-03-1339){ref-type="fig"}). The expression levels of ERK1-SNO were significantly attenuated following transfection of U251 cells with the ERK1^C183A^ plasmid ([Fig. 5B and C](#f5-ijmm-41-03-1339){ref-type="fig"}). These results suggested that mutation at Cys^183^ may partially prevent S-nitrosylation of ERK1/2 in glioma cells.

Preventing S-nitrosylation of ERK1 promotes ERK phosphorylation and cell survival
---------------------------------------------------------------------------------

To determine the relationship between ERK1/2 nitrosylation and phosphorylation, U251 glioma cells were transfected with either ERK1^WT^ or ERK1^C183A^ plasmids, and were then treated with GSNO (500 *µ*M). The results indicated that the expression levels of p-ERK were significantly decreased in the ERK1^WT^-transfected cells when GSNO was added ([Fig. 6A and B](#f6-ijmm-41-03-1339){ref-type="fig"}), which was consistent with the previous findings presented in [Fig. 3D](#f3-ijmm-41-03-1339){ref-type="fig"}. However, GSNO failed to reduce p-ERK1/2 levels when U251 cells were transfected with the ERK1^C183A^ mutant ([Fig. 6A and B](#f6-ijmm-41-03-1339){ref-type="fig"}). These findings indicated that preventing ERK1 S-nitrosylation may increase the phosphorylation of ERK1/2 in glioma cells.

The present study also investigated the effects of ERK1 S-nitrosylation prevention on the survival of glioma cells. In line with the data presented in [Fig. 1](#f1-ijmm-41-03-1339){ref-type="fig"}, cell viability was significantly reduced following treatment with GSNO; however, the reduction in cell viability was reversed by a point mutation at Cys^183^ of ERK1 ([Fig. 6C](#f6-ijmm-41-03-1339){ref-type="fig"}). Furthermore, western blot analysis demonstrated that GSNO treatment induced an increase in cleaved caspase-3 expression; however, this was reversed following transfection with the ERK1^C183A^ mutant ([Fig. 6D and E](#f6-ijmm-41-03-1339){ref-type="fig"}). In addition, flow cytometric apoptotic assay indicated that the percentage of U251 apoptotic cells transfected with ERK1^C183A^ mutant was significantly reduced following GSNO treatment compared with in the cells transfected with the ERK1^WT^ plasmid ([Fig. 6F](#f6-ijmm-41-03-1339){ref-type="fig"}). Taken together, these results suggested that preventing S-nitrosylation of ERK1, via transfection with a ERK1^C183A^ mutant, partially reversed GSNO-induced decreases in ERK phosphorylation and cell survival in U251 glioma cells.

Alterations in ERK1/2 phosphorylation and S-nitrosylation levels in human glioma tissues
----------------------------------------------------------------------------------------

Western blot analysis was employed to detect p-ERK1/2 and total ERK1/2 levels, and a biotin switch assay followed by western blot analysis was used to measure ERK1/2-SNO levels, in 9 noncancerous brain tissues and 33 glioma specimens (n=11/grade). As presented in [Fig. 7](#f7-ijmm-41-03-1339){ref-type="fig"}, the expression levels of p-ERK1/2 were increased in high-grade glioma tissues, particularly in glioma grade III ([Fig. 7A and B](#f7-ijmm-41-03-1339){ref-type="fig"}), whereas there was a marked reduction in ERK1/2-SNO levels in glioma tissues, which was also evident in glioma grade III ([Fig. 7A and C](#f7-ijmm-41-03-1339){ref-type="fig"}). These data provided *in vivo* evidence for the possible influence of ERK1/2 S-nitrosylation on ERK1/2 phosphorylation during glioma proliferation.

Discussion
==========

NO donors, SNP and GSNO, breakdown to release NO and exert an inhibitory effect on cell survival in glioma cells. In the present study, NO donor treatment induced a significant decrease in p-ERK1/2 expression ([Fig. 3](#f3-ijmm-41-03-1339){ref-type="fig"}) and a marked increase in ERK1/2-SNO levels ([Fig. 4](#f4-ijmm-41-03-1339){ref-type="fig"}) in U251 cells, thus suggesting a link between ERK1/2-SNO and p-ERK/2. Further mutational analysis demonstrated that Cys^183^ was vital for S-nitrosylation of ERK1 ([Fig. 5](#f5-ijmm-41-03-1339){ref-type="fig"}) and that preventing the formation of ERK-SNO by ERK1^C183A^ mutation reversed NO-induced suppression of cell viability and p-ERK1/2 expression, and increased cell apoptosis of glioma cells ([Fig. 6](#f6-ijmm-41-03-1339){ref-type="fig"}). In addition, increased p-ERK1/2 levels were observed in human glioma tissues, which were accompanied by a marked decrease in ERK1/2-SNO levels ([Fig. 7](#f7-ijmm-41-03-1339){ref-type="fig"}). These findings indicated a novel mechanism underlying the antitumor role of NO-associated chemicals and provided insights into gene therapy targeting the ERK1/2 pathway in glioma.

NO is a free radical, which predominantly functions as a messenger or effector molecule. Previous studies have reported that the viability of U87 and C6 cells may be significantly inhibited following exposure to high concentrations of NO donors ([@b15-ijmm-41-03-1339],[@b17-ijmm-41-03-1339]). The present study demonstrated that treatment with the NO donors SNP or GSNO resulted in a significant reduction in the viability of U251 cells. These data suggested that the inhibitory effects of NO on cell survival could be generalized in various glioma cell lines. However, previous evidence also suggests that NO displays stimulatory and inhibitory effects in the context of cell survival and apoptosis. Maejima *et al* reported that low doses of the NO donor S-mitroso-N-acetyl-D,L-penicillamine favor cell survival, whereas high doses may reduce cell viability of cardiomyocytes ([@b18-ijmm-41-03-1339]). Lechner *et al* demonstrated that low levels of NO produced by the tumor microenvironment favor tumor cell survival, whereas tumor cells with high NO levels undergo cell death ([@b19-ijmm-41-03-1339]). The dual effects of NO may be ascribed to the availability of enzymes, timing of apoptotic stimuli, redox state, donor doses, spatial location of key reactants and interactions with other molecules ([@b20-ijmm-41-03-1339]).

S-nitrosylation is involved in the regulation of numerous biological processes, including cell proliferation and survival, and particularly apoptosis ([@b11-ijmm-41-03-1339],[@b21-ijmm-41-03-1339]). S-nitrosylation of B-cell lymphoma 2 enhances its stability, inhibits ubiquitous degradation in numerous tumor types and induces resistance to *cis*-platinum chemotherapy in breast cancer ([@b22-ijmm-41-03-1339],[@b23-ijmm-41-03-1339]). Furthermore, S-nitrosylation of the death receptor Fas initiates its redistribution on lipid rafts and promotes Fas ligand-mediated apoptosis in cancer ([@b24-ijmm-41-03-1339]). ERK1 harbors six Cys residues, as indicated in [Fig. 5A](#f5-ijmm-41-03-1339){ref-type="fig"}. Cys^183^ is the most probable site for S-nitrosylation, according to the S-nitrosylation motif (K/R/H/D/E+C+D/E) reported previously ([@b16-ijmm-41-03-1339]). The present study indicated that ERK1/2 may be nitrosylated by the NO donor GSNO, and that replacing Cys^183^ with alanine may prevent the S-nitrosylation of ERK1/2 in glioma cells. The small decrease in ERK1-SNO levels in response to Cys^183^ mutation indicates that other ERK1 Cys residues may also contribute to S-nitrosylation. Nevertheless, the ERK1^C183A^ mutation significantly reversed GSNO-induced suppression of cell viability and enhancement of apoptosis of glioma cells. Together with a previous study in breast cancer cells ([@b12-ijmm-41-03-1339]), these findings suggested that ERK-SNO may promote tumor cell apoptosis.

Within the MAPK cascades, the ERK1/2 signaling pathway is a principle pathway that regulates cell proliferation and survival when activated by phosphorylation at Thr^202^ and Tyr^204^ residues of ERK1 ([@b5-ijmm-41-03-1339],[@b25-ijmm-41-03-1339]). Activation of ERK1/2 signaling in glioma tissues, as determined by increased p-ERK1/2 levels, has been detected in the present study, as well as in previous studies ([@b7-ijmm-41-03-1339],[@b8-ijmm-41-03-1339]). The S-nitrosylation site Cys^183^ is spatially close to Thr^202^ and Tyr^204^, thus suggesting the possibility of mutual regulation between S-nitrosylation and phosphorylation of ERK1/2. The present *in vitro* results indicated that treatment with GSNO induced a reduction in p-ERK1/2 expression, an increase in ERK1/2-SNO levels, and cell growth inhibition in glioma cells. I*n vivo*, the results demonstrated that p-ERK1/2 levels were increased, whereas ERK1/2-SNO levels were decreased in glioma tissues, particularly in glioma grade III. Furthermore, a point mutation at Cys^183^ confirmed that preventing formation of ERK1-SNO significantly increased p-ERK1/2 expression and reversed GSNO-induced cell apoptosis in U251 glioma cells. These findings suggested a regulatory role of ERK1/2 S-nitrosylation on ERK1/2 phosphorylation, which may provide novel information regarding ERK1/2 targeting in glioma therapy.

In addition to ERK1/2, other important signaling proteins are also modified by S-nitrosylation. Murillo-Carretero *et al* reported that S-nitrosylation of epidermal growth factor receptor (EGFR) inhibited EGFR phosphorylation and cell proliferation in neuroblastoma cells ([@b26-ijmm-41-03-1339]). In head and neck squamous cell carcinoma, S-nitrosylation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor (NF)-κB inhibited phosphorylation of STAT3 and activation of NF-κB, and decreased cell proliferation and increased apoptosis ([@b27-ijmm-41-03-1339]). These studies indicated a critical role of S-nitrosylation in the regulation of protein phosphorylation and cellular biological functions. Notably, several NO-hybridized drugs have been developed to inhibit cancer cell growth *in vitro* and *in vivo* ([@b28-ijmm-41-03-1339],[@b29-ijmm-41-03-1339]), thus suggesting the potential translational relevance of NO-mediated S-nitrosylation in the future.

A few limitations should be mentioned with regards to the present study. All *in vitro* work presented in this study was performed in U251 glioma cells. In this respect, duplication of efforts in other glioma cell lines would be beneficial. In addition, it is necessary to perform brain xenograft experiments to confirm the inhibitory role of ERK1 S-nitrosylation on ERK1/2 phosphorylation and glioma growth.

In conclusion, NO donor treatment inhibited cell survival and induced apoptosis of U251 glioma cells. S-nitrosylation of ERK1/2 and ERK1/2 phosphorylation exhibited inverse alterations in GSNO-treated glioma cells and in human glioma tissues. Preventing ERK1 nitrosylation via a mutation at Cys^183^ partially reversed NO-induced decreases in ERK phosphorylation and cell survival. These findings revealed a novel mechanism of ERK1/2 underlying tumor cell development and apoptotic resistance of glioma.
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![NO donor treatment inhibits the growth of U251 glioma cells. (A and B) Results of a CCK-8 assay indicated a concentration-dependent decrease in the viability of U251 glioma cells following exposure to 0--2 mM SNP or 0--500 *µ*M GSNO for 36 h. (C and D) CCK-8 assay exhibited a reduction in cell viability at different time-points following SNP (2 mM) or GSNO (500 *µ*M) treatment. Relative absorbance was normalized to the untreated group (0). ^\*^P\<0.05 and ^\*\*\*^P\<0.001 compared with the untreated group (0). CCK-8, Cell Counting kit-8; GSNO, S-nitrosoglutathione; NO, nitric oxide; SNP, sodium nitroprusside.](IJMM-41-03-1339-g00){#f1-ijmm-41-03-1339}

![NO donors SNP and GSNO can release NO into the medium of cultured glioma cells. The Griess method was used to quantify NO levels in the culture supernatant of U251 cells following (A) 1 and 2 mM SNP or (B) 250 and 500 *µ*M GSNO treatment. ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001 compared with the untreated group (0). GSNO, S-nitrosoglutathione; NO, nitric oxide; SNP, sodium nitroprusside.](IJMM-41-03-1339-g01){#f2-ijmm-41-03-1339}

![NO donor treatment attenuates ERK1/2 phosphorylation in U251 glioma cells. (A and B) Alterations in p-ERK1/2 expression at the indicated time-points following SNP (2 mM) or GSNO (500 *µ*M) treatment were detected by western blotting and were semi-quantified. (C and D) Alterations in p-ERK1/2 expression following treatment with the indicated concentrations of SNP or GSNO were examined by western blotting and were semi-quantified. p-ERK1/2 expression was normalized to total ERK1/2. ^\*^P\<0.05 and ^\*\*^P\<0.01 compared with the control group (0). ERK1/2, extracellular signal-regulated kinase 1/2 GSNO, S-nitrosoglutathione; NO, nitric oxide; p-ERK1/2, phosphorylated-ERK1/2; SNP, sodium nitroprusside.](IJMM-41-03-1339-g02){#f3-ijmm-41-03-1339}

![NO donor treatment promotes S-nitrosylation of ERK1/2 in U251 glioma cells. (A) Cells were treated with 500 *µ*M GSNO for the indicated time and ERK1/2-SNO was detected by biotin switch assay followed by western blotting. (B) Cells were treated with 250 and 500 *µ*M GSNO for 24 h and the level of ERK1/2-SNO was detected as aforementioned. Total ERK1/2 was used as an endogenous control. ERK1/2, extracellular signal-regulated kinase1/2; GSNO, S-nitrosoglutathione; NO, nitric oxide; SNO, S-nitrosothiol.](IJMM-41-03-1339-g03){#f4-ijmm-41-03-1339}

![Point mutation at Cys^183^ partially prevents S-nitrosylation of ERK1 in glioma cells. (A) Location of Cys and the adjacent amino acids in the ERK1 protein sequence. The red \'C\' in the middle of each box is cysteine residue. (B) Transfection efficiency and S-nitrosylation of ERK1^WT^ and ERK1^C183A^ were determined by biotin switch assay, followed by western blotting. (C) Semi-quantitative analysis of ERK1-SNO levels. β-actin was used as a loading control. ^\*^P\<0.05 compared with the ERK1^WT^ group. Cys, cystein; ERK, extracellular signal-regulated kinase; SNO, S-nitrosothiol; IB, immunoblotting; WT, wild-type.](IJMM-41-03-1339-g04){#f5-ijmm-41-03-1339}

![Preventing S-nitrosylation of ERK1 promotes ERK phosphorylation and cell survival, and suppresses apoptosis. Following transfection of U251 glioma cells with ERK1-Flag or ERK1 mutant form (ERK^C183A^), cells were treated with 500 *µ*M GSNO for 24 h. (A and B) p-ERK1/2 was detected by western blotting and was semi-quantified. p-ERK1/2 levels were compared with β-actin levels, and results were normalized to vector group. (C) Cell Counting kit-8 assay was performed to examine the viability of U251 glioma cells. Cell survival percentage was normalized to the vector group. (D and E) Caspase-3 protein expression was detected by western blotting and semi-quantified. Cleaved caspase-3 levels were compared with β-actin levels, and results were normalized to the vector group. The lower panel of cleaved caspase-3 blot in part D was obtained after a longer exposure time compared with the upper panel. (F) Flow cytometric detection of apoptosis of U251 glioma cells. The percentage of apoptotic cells was quantified and compared. ^\*^P\<0.05, ^\*\*^P\<0.01 and ^\*\*\*^P\<0.001. IB, immunoblotting; ERK, extracellular signal-regulated kinase; fITC, fluorescein isothiocyanate; GSNO, S-nitrosoglutathione; p-ERK1/2, phosphorylated ERK1/2; PI, propidium iodide; WT, wild-type.](IJMM-41-03-1339-g05){#f6-ijmm-41-03-1339}

![Alterations in the levels of ERK1/2 phosphorylation and S-nitrosylation in noncancerous and glioma tissues. In noncancerous brain samples (n=9) and various grades of glioma (n=11 for each grade), western blotting was used to detect the expression levels of p-ERK1/2 and total ERK1/2 levels, and biotin switch assay followed by western blotting was employed to detect ERK1/2-SNO. (A) Representative blot images are presented. Semi-quantification for the ratio of (B) p-ERK1/2/total ERK1/2 and (C) ERK1/2-SNO/total ERK1/2. ^\*^P\<0.05 compared with the noncancerous group. ERK1/2, extracellular signal-regulated kinase 1/2; p-ERK1/2, phosphorylated-ERK1/2; SNO, S-nitrosothiol.](IJMM-41-03-1339-g06){#f7-ijmm-41-03-1339}

###### 

Clinicopathological characteristics of the studied subjects.

  Case no.   Code no.   Gender   Age (years)   Location                              WHO grade
  ---------- ---------- -------- ------------- ------------------------------------- --------------
  1          919616     M        57            Right cerebellum                      Noncancerous
  2          912226     F        54            Right temporal lobe                   Noncancerous
  3          972078     F        49            Not available                         Noncancerous
  4          968605     F        69            Not available                         Noncancerous
  5          981488     M        41            Cerebellum                            Noncancerous
  6          1095392    M        32            Not available                         Noncancerous
  7          1004728    M        63            Right frontal lobe                    Noncancerous
  8          941814     M        20            Cerebellum                            Noncancerous
  9          928412     M        48            Not available                         Noncancerous
  10         970570     M        52            Right frontal lobe                    Grade II
  11         1157139    M        42            Right frontal lobe                    Grade II
  12         1145933    F        48            Right frontal lobe                    Grade II
  13         1140811    F        49            Right frontal lobe                    Grade II
  14         1164493    M        64            Left insular lobe                     Grade II
  15         1190502    M        31            Left frontal lobe                     Grade II
  16         1158620    M        43            Right temporal lobe                   Grade II
  17         1196273    M        40            Left frontal lobe                     Grade II
  18         1152968    F        63            Left temporal lobe                    Grade II
  19         1110685    F        27            Right frontal lobe                    Grade II
  20         1084447    F        52            Not available                         Grade II
  21         999737     M        52            Left frontal-temporal lobe            Grade III
  22         920498     M        50            Right temporal-parietal lobe          Grade III
  23         926714     M        56            Bilateral temporal lobe               Grade III
  24         1164248    F        66            Left frontal lobe                     Grade III
  25         1191197    M        68            Left parietal-occipital lobe          Grade III
  26         922050     F        19            Right frontal lobe                    Grade III
  27         1117547    M        47            Right temporal lobe                   Grade III
  28         1081283    F        58            Left temporal lobe                    Grade III
  29         947804     F        66            Left frontal-temporal-parietal lobe   Grade III
  30         1145935    M        23            Cervical cord                         Grade III
  31         1029589    M        31            Right frontal-temporal lobe           Grade III
  32         1147279    F        64            Cerebellum                            Grade IV
  33         1147166    M        58            Left frontal-temporal lobe            Grade IV
  34         1141904    M        47            Right temporal lobe                   Grade IV
  35         1132842    F        62            Left temporal lobe                    Grade IV
  36         1119597    F        50            Right frontal lobe                    Grade IV
  37         1096129    M        61            Left temporal lobe                    Grade IV
  38         1077922    M        43            Left temporal lobe                    Grade IV
  39         1140776    M        26            Right parietal-occipital lobe         Grade IV
  40         1088070    F        58            Right temporal lobe                   Grade IV
  41         1164493    M        66            Left insular lobe                     Grade IV
  42         1184604    F        34            Right temporal lobe                   Grade IV

F, female; M, male; WHO, World Health Organization.
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